CD24-dependent innate immune checkpoint targeting chimera disrupts TGF-β-driven immunosuppression to enhance anti-tumor therapy
The immunosuppressive tumor microenvironment (TME) poses formidable challenges for cancer immunotherapies. Among the complex TME landscape, the cytokine TGF-{beta}1 is an attractive soluble target for reinvigoration of anti-tumor immunity due to its pivotal function in immune cell suppression, extracellular matrix remodeling, and epithelial-to-mesenchymal transition (EMT) promotion, while immune…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
